Table 1.
Treatment group | Dose mg/kg | AST (U/L) | ALT (U/L) | GGT (U/L) | ALP (U/L) | Bilirubin (mg/dL) |
---|---|---|---|---|---|---|
Normal | 106.15 ± 4.36 | 37.91 ± 1.61 | 3.26 ± 0.21 | 308.83 ± 8.81 | 0.5 ± 0.02 | |
CCl4 | 1.25 | 379.83 ± 11.70∗∗∗a | 303.83 ± 12.12∗∗∗a | 18.20 ± 0.89∗∗∗a | 586.16 ± 11.92∗∗∗a | 2.74 ± 0.1∗∗∗a |
AM + CCl4 | 250 | 322.50 ± 12.08∗∗b | 264.83 ± 10.74∗b | 12.41 ± 0.73∗∗∗b | 512.0 ± 11.40∗∗b | 1.66 ± 0.10∗∗∗b |
AM + CCl4 | 500 | 283.66 ± 9.82∗∗∗b | 178.16 ± 6.27*** | 6.90 ± 0.38∗∗∗b | 398.50 ± 0.48∗∗∗b | 1.16 ± 0.10∗∗∗b |
Silymarin + CCl4 | 10 | 166.16 ± 9.34b | 99.75 ± 3.55*** | 5.78 ± 0.26∗∗∗b | 325 ± 33 ± 12.10∗∗b | 0.94 ± 0.04∗∗b |
All values represent mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; ANOVA, followed by Dunnett's multiple comparison test. aAs compared with normal group. bAs compared with CCl4 only group.